This mechanism, including the NAD+-dependent increase in TET1 activity and further activation of the IRF1-PD-L1 axis, was associated with decreased antitumor immune responses in hepatocellular carcinoma tissue samples [69]. The gene discussed is IRF1; the disease is hepatocellular carcinoma.